D-Pharm Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From D-Pharm Ltd.
Novartis’ Gene Therapy Luxturna Gets Routine Funding In Scotland
Scotland’s health technology assessment body has granted routine reimbursement to Novartis’ vision loss drug Luxturna after an interim funding period via its ultra-orphan pathway, while Chiesi’s Filsuvez is set to begin its journey on the same pathway.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
What Do FTC’s Aggressive Moves Against Biopharma Portend For 2024?
The Federal Trade Commission blocked or restricted several deals last year, broadening what it considers to be anticompetitive transactions. Stakeholders are looking to see if the agency will bring similar cases this year and what remedies it will seek to allow deals to go forward.
Keeping Track: Return & Renewal At US FDA
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Thrombotech Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice